Equities Analysts Offer Predictions for BCRX Q2 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $0.10 per share for the quarter, up from their previous estimate of ($0.01). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.56 EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $1.29 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the previous year, the business posted $0.28 EPS. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year.

Several other research firms have also commented on BCRX. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $16.56.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $9.98 on Thursday. The company’s fifty day moving average price is $7.87 and its 200-day moving average price is $7.89. BioCryst Pharmaceuticals has a 1-year low of $5.23 and a 1-year high of $11.11. The firm has a market capitalization of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $32,000. GF Fund Management CO. LTD. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter worth about $33,000. GAMMA Investing LLC increased its stake in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $46,000. Finally, R Squared Ltd purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.